Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.

Researchers have made a groundbreaking discovery in the field of hematology, providing an explanation for spontaneous and unusual blood-clotting that continues to occur despite treatment with ...

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...

Safety profile of lutetium-177 in patients with impaired renal function: A retrospective analysis of adverse events in mCRPC treatment. Dr. Saylani highlighted that Lutetium-177 vipivotide tetraxetan ...

For the past month, local basketball programs have teamed up to raise awareness and spread hope for 9-year-old Autumn and ...

The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor ...

In a recent study, non-invasive prenatal testing was able to help researchers diagnose fetal anemia earlier during pregnancy.

Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Research highlights the critical role of red meat in providing essential nutrients like iron, zinc, and B12, particularly for ...

In addition to the prolonged pain and suffering endured by sickle cell patients, a Washington University School of Medicine study has concluded that there could be a significant impact on cognitive ...